Category Archives: stocks to watch

Posted on by

Can this company achieve what hasn’t been done in 20 years?

Everyone is aware of tobacco / cigarette companies and their stocks. For many investors, these are absolute core investments for their stability and high dividends. Against all negativity and a shrinking pool of smokers, tobacco companies managed to survive and thrive. Almost a year ago, my Premium PLUS members received an exclusive report from me with an idea with ties to this sector — but from an entirely different viewpoint. I am making this case public now, discussing the rollercoaster that’s behind us, but also what’s ahead of us.

Continue reading →
Posted on by

Investing in stocks of bankrupt companies + new research report

Investing in stocks of companies that went bankrupt, seriously? Seriously! What at first sounds like a recipe for disaster, indeed can be a lucrative endeavor. A bankrupt company is not the same as the ceasing of operations. Indeed, often it is even the case that companies go into bankruptcy restructuring while everyday operations continue. This area can be a great treasure trove to fish for potential multi-baggers where others don’t bother due to negative associations. A premier on Financial Engineering: My Premium PLUS members receive my latest stock idea – a pick that recently emerged from bankruptcy – with the potential to multi-bag.

Continue reading →
Posted on by

B&O: Back with a Bang?

Danish high-end consumer electronics maker Bang & Olufsen has been struggling ever since the Great Recession. It is not surprising that the stock is down from its highs in 2006–2007. However, I was indeed a bit surprised that it’s down by a staggering 98%! Even since a temporary recovery attempt that culminated in 2018, the stock has fallen by more than 90%! Over the last twelve months, though, shares are up by 46%. Management has ambitious plans to bring the struggling brand back on track. Could this be now a good entry point?

Continue reading →
Posted on by

Is Insmed a Promising Biotech Blockbuster? + new research report

Insmed, a biotech company with one approved drug and a very promising pipeline, in the last 13 months saw its stock going up by a factor of no less than 4x – plus 300%! There were two key events each propelling the stock decisively higher. Both were updates on ongoing clinical trials only. I am saying deliberately “only”, because it is not even a given that biotechs surge so much after drugs get approved by the FDA, yet, here it happened twice following just updates to clinical trials. The reason: Insmed’s assets are very promising with each potentially achieving blockbuster status (> 1 bn. USD is sales, both potentially multi-billions). Is it now time to jump onto this precious opportunity? My Premium PLUS members will soon receive my latest stock idea with a much more attractive setup.

Continue reading →
Posted on by

The case of e.l.f. Beauty — chic story meets a glamorous valuation

The comparatively young company e.l.f. Beauty is famous among younger generations thanks to low-price, high-value and cruelty-free cosmetics. Its stunning rise, disrupting the industry with bold innovation, has glossed its stock with a remarkable run, reflecting glamorous growth and consistent market share gains for years. After its peak, the stock fell by three quarters and has more than doubled again since then. After the latest earnings, shares surged by more than 20% as a big acquisition was announced. Is this a beautiful compounder to have an eye on?

Continue reading →
Posted on by

WD-40: an overlooked portfolio lubricant?

Last Sunday, I finally went after an annoying task that had been waiting for me for too long: to remove sticky and really ugly glue from an entire big window frame. My first attempts failed miserably and I had left it untouched for some time. But that stuff needed to be finally done. After some research, I found the solution: WD-40, the home workers best friend. While in full swing, I remembered that WD-40 is also a publicly listed company! The stock has practically always been extremely expensive, but I haven’t covered it for years. Time for an update to answer the question whether this is a smooth slide or a rusty bet.

Continue reading →
Posted on by

Third time’s the charm? Is Capri finally a buy?

I already discussed the stock of Capri Holdings twice last year, prior to and after the failed takeover attempt by Tapestry. Capri’s stock fell even below my lower target of 20 USD from initially 35 USD. Now, sitting around 15 USD and having announced the sale of troubled Versace, many things have changed, requiring a reassessment of the case. If the sale goes through, the balance sheet flips from net debt to net cash at current figures. Also, loss-making Versace will stop to be a burden for the group. Is the third time now finally the charm?

Continue reading →
Posted on by

Is Fannie Mae really a safe multi-bagger?

Readers who like spicier ideas by now might have heard about ongoing discussions of a potential release of two (in)famous US mortgage companies from conservatorship, i.e. a possible privatization. Yes indeed, state-owned (or partly-owned) enterprises aren’t just a thing of perceived socialist or communist countries. At the latest after none other than hedge fund billionaire Bill Ackman pitched his investment case aggressively on Twitter, stocks of Fannie Mae and Freddie Mac have made big waves. According to Ackman, there’s still a substantial upside of 5x left (after already being up by 5x since November). Is this THE no-brainer opportunity for 2025?

Continue reading →
Posted on by

Halozyme Therapeutics – an overlooked bargain? + new stock idea

Feeling uncomfortable with everybody’s darling stocks, my motivation was and still is to find stock ideas with what I call “an own life”. With that I am looking for companies with internal triggers or catalysts which can influence shares positively (almost) regardless of what broader markets do. While I do not believe (for now) in a hefty stock market crash which pushes down all equities, I cannot rule out a nosebleed correction in the tech sector. In search of uncorrelated stock ideas, I spent some time on the Pharma / biotech sector. Halozyme Therapeutics is a seemingly lowly-valued stock. My Premium PLUS members have already received my latest potential-multi-bagger stock idea in an exclusive research report to kick off the year 2025.

Continue reading →
Posted on by

Stocks of Dollar Stores – now finally a buy?

This Weekly is an update taking a second look at North American “dollar store” operators Dollar General and Dollarama. After almost exactly to the day two years ago, I featured both names in an analysis concluding that I have sympathies for the businesses as such, but not for their stocks. Something quite interesting has happened since: one stock totally cratered, the other advanced by another 75%. The development could not have been more different! What do both have in store now?

Continue reading →